Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Current Leases (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Current Leases for 4 consecutive years, with $696000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 76.2% to $696000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $696000.0, a 76.2% increase, with the full-year FY2024 number at $550000.0, down 15.25% from a year prior.
  • Current Leases was $696000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $642000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $747000.0 in Q3 2023 to a low of $350000.0 in Q2 2024.
  • A 4-year average of $601750.0 and a median of $645500.0 in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: plummeted 51.99% in 2024, then surged 83.43% in 2025.
  • Orchestra BioMed Holdings' Current Leases stood at $697000.0 in 2022, then decreased by 6.89% to $649000.0 in 2023, then decreased by 15.25% to $550000.0 in 2024, then grew by 26.55% to $696000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Current Leases are $696000.0 (Q3 2025), $642000.0 (Q2 2025), and $590000.0 (Q1 2025).